This test is most useful if any of these apply to you.
If you take a probiotic capsule every morning, you may want to know whether that organism leaves any trace in stool. This test answers the narrower question. It uses a DNA-counting method to measure Lactobacillus acidophilus in stool, and in research settings similar assays have been used to confirm that an ingested strain's DNA appeared after dosing.
What it does not do is grade your gut health. L. acidophilus is usually a minor member of the adult gut community, often sitting below what a lab can detect unless you are eating or supplementing it. A low number is often normal. Read this as a transit check, not a report card.
The assay uses quantitative real-time PCR. PCR is a lab method that copies a chosen stretch of DNA until there is enough to count. The short starter sequences in the assay usually target either the 16S ribosomal gene or the spacer between two ribosomal genes, regions that differ enough between closely related lactobacilli to help tell them apart.
That matters because L. acidophilus belongs to a cluster of species that can look alike under a microscope and behave alike in culture. DNA is usually the cleanest way to separate them in a stool assay.
Published strain-specific stool assays report detection floors in the range of tens of thousands of cells per gram of stool. Below that floor, the result reads as absent, which is not the same as zero.
PCR does not tell you whether the bacteria were alive. It counts DNA. Dead cells from a heat-killed preparation or from bacteria that died in transit can still carry countable DNA. So a positive result confirms that the organism's genetic material reached your stool, not that a living colony is growing in your colon.
Large stool DNA surveys show that lactobacilli are a small part of the adult fecal microbiome. L. acidophilus itself is often near or below the detection floor in people who are not supplementing. That is the first fact to remember.
So the obvious reading, low means depleted and depleted means unhealthy, is wrong most of the time. The colon is not where this organism naturally dominates. It is more often a passenger, topped up by certain yogurts, kefir, fermented foods, and capsules.
There is a second reason a single number tells you little. A one-year longitudinal study of 75 adults in Sweden found that variation within the same person accounted for 23% of total variance in gut microbiome composition, and oxygen-tolerant bacteria such as L. acidophilus shifted more than many other species. A separate daily-sampling study of 20 adults found substantial day-to-day swings across most gut bacterial genera, with stool moisture and recent diet among the drivers.
The most consistent human finding on this marker is simple: supplementation raises the stool count while you are taking it, and the count falls back toward baseline once you stop.
In a randomized double-blind trial in adults with irritable bowel syndrome, four weeks of a fermented milk containing L. acidophilus La-5 plus added fiber raised strain-specific DNA in stool. After one week off the product, levels had dropped close to where they started. In a trial of 50 children with atopic dermatitis, the group assigned to L. acidophilus NCFM had fecal counts rise from mostly undetectable to clearly detectable after the intervention, while the broader gut community changed little.
In preterm infants given a two-strain product, Bifidobacterium bifidum established longer-term colonization while fecal L. acidophilus dropped sharply once dosing stopped. Two organisms, same capsule, different fates.
If you want to know whether a product is getting through, test while you are taking it. Do not expect the strain to take up permanent residence. That is not how this organism usually behaves in adults.
The assumption baked into a lot of probiotic marketing is that more of this bacterium equals a healthier gut. Human data do not support that as a general rule.
Studies measuring fecal Lactobacillus at the genus and species-cluster level, a broader measurement than this stool test, have found net increases in liver cirrhosis, type 2 diabetes, and inflammatory bowel disease, while hypertension showed relative depletion. A duodenal sampling study, which measured the small bowel rather than stool, found L. acidophilus much more abundant in people who were overweight than in normal-weight controls, and inversely related to HDL cholesterol.
These findings do not mean L. acidophilus causes those conditions. They mean the number is context-dependent. A high reading in someone taking a probiotic usually means the product's DNA is showing up in stool. A high reading in someone taking nothing may mean their gut environment favors lactic acid bacteria. In some disease states, that can be a sign of a disrupted community rather than a defense against it.
Some clinical states do show reduced levels, though these are correlations from small cross-sectional studies, not proof that the deficit caused the disease.
In people with non-cirrhotic chronic hepatitis C, fecal L. acidophilus counts were lower than in healthy controls. Within the hepatitis group, levels did not track with how severe the liver scarring was, which weakens any story about it driving disease progression. Lower lactobacilli can also appear after antibiotics and in the underdeveloped gut of premature infants, where a randomized trial of 68 preterm neonates found that a dual-strain product raised genus-level Bifidobacterium and Lactobacillus and suppressed a cluster of Clostridium bacteria.
None of these findings supports using a low reading to diagnose anything. Mendelian randomization work, which uses inherited genetic differences to probe cause and effect, found a possible causal link between gut Lactobacillus genus abundance and acute gingivitis risk. That is a signal, not a clinical tool, and it is not species-specific to this test.
Several things distort this number without telling you much about your health.
Stool consistency matters too. Daily sampling work found stool moisture among the host factors most tied to day-to-day swings in bacterial counts. Test during a period of typical bowel habits.
Given how much this number moves within the same person, a single result is hard to interpret on its own. The value is in the comparison.
The cleanest design is a before-and-during pair. Test at baseline, before starting or after a washout from the product. Start the product. Test again three to four weeks in, while still taking it. If the number rises, the product's DNA is reaching your stool. If it does not move, the product may not contain much of the target organism by the time you take it, the organism may not be reaching stool, or the assay's starter sequences may not match the strain in your capsule.
Retest when the question changes: a new product, a course of antibiotics, or a repeat of the same experiment under the same conditions. Routine annual tracking of this single organism has not been validated.
If your number is low and you are not supplementing, nothing needs to happen. That is the normal state for many adults.
If the number is low while you are actively taking a high-dose probiotic, the useful next step is usually a product change rather than a medical workup. Check that the label names a specific strain rather than just a species, and check storage conditions. Retest four weeks into the new product if you still want to answer the transit question.
If the result comes alongside real symptoms, the single-species number is the least informative part of the picture. A broader stool panel that covers digestion markers, inflammation markers such as fecal calprotectin, and pathogen detection will tell you far more than any single count of a normally present bacterium. Persistent diarrhea, blood in stool, unexplained weight loss, or symptoms lasting more than a few weeks warrant a gastroenterology evaluation, and the workup should start with those broader markers, not with this one.
If you are considering probiotics while immunocompromised, or with a central line, a damaged gut barrier, or critical illness, talk to a clinician first. Probiotic-associated bloodstream infections have been documented in ICU patients with central venous catheters, and baseline stool counts are not used to decide who can safely take live probiotics.
Evidence-backed interventions that affect your Lactobacillus Acidophilus level
Lactobacillus Acidophilus is best interpreted alongside these tests.